COMPANY:

InnoSIGN

"Poster presentation not to be missed at ENA...'Quantification of PI3K/AKT/mTOR pathway inhibition is predictive of biological response'...By using InnoSIGN Comprehensive Pathway Analysis (CPA) it is possible to quantitatively measure the capacity of drugs to inhibit activity of the pathways (like PI3K) and to correlate its activity directly to biological response."

"InnoSIGN...announced that it has launched a suite of products and services with this platform directed at supporting biopharma’s development activities...InnoSIGN uses a novel biology-first approach to analyze the functional activities of the cellular pathways, thereby capturing the complexity of millions of possible signaling events and determining the most salient pathways related to diseases."

"NYU Langone Health published their study in Journal of Clinical Pathology showing that increased PI3K pathway activity, independent of PIK3CA mutations, may play a role in the recurrence of early-stage breast cancer with low and intermediate 21-gene RS."

"The InnoSIGN team...during the San Antonio Breast Cancer Symposium (SABCS), from Wednesday December 6 to Friday 8 December, 2023...An abstract by NYU-Langone and two abstracts by InnoSIGN have been selected for poster presentation in the scientific program."

"The InnoSIGN team is excited to meet you at this year’s AMP Annual Meeting & Expo in Salt Lake City, US, from Tuesday November 14 to Saturday 18 November, 2023...Applications of OncoSIGNal pathway profiling platform in breast cancer and bladder cancer will be presented at the InnoSIGN corporate workshop..."

"...InnoSIGN Inc...announces the offering of its OncoSIGNal pathway profiling platform for clinical use as a Laboratory Developed Test (LDT) through InnoSIGN’s high-complexity CLIA laboratory...OncoSIGNal is the first platform identifying the tumor-driving cell signaling pathways in tumor tissue."

"InnoSIGN B.V. and the Catharina Hospital Eindhoven receive a grant of almost € 700 000 by the European subsidy program OPZuid for the 'STA-OP' multicenter prospective clinical trial, starting April 2023 (for 3 years). The objective of this trial is to identify new personalized targeted therapies based on 'Signal Transduction pathway Activity for recurrent Ovarian cancer Patients'...In this clinical trial InnoSIGN’s proprietary OncoSIGNal technology will be used to identify the tumor driving cell signaling pathways in the patient tumor tissue to direct patients to personalized therapies with targeted drugs that inhibit the activity of these pathways."

"...Institut Gustave Roussy, published in Clinical Cancer Research their findings using OncoSIGNal for prostate cancer...'Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors'...It is shown that Low AR activity, activation of stemness programs, and Hedgehog pathway were associated with primary androgen receptor axis inhibitors’ resistance, whereas most acquired resistance was associated with subclonal evolution, AR-related events, and neuroendocrine differentiation."

"Joy Zhou Done from Johns Hopkins Hospital will present her findings on racial differences in ER staining positive breast cancer during the American Society of Breast Surgeons 24th Annual Meeting in Boston, US...By using OncoSIGNal there were measurable differences in ER pathway activity between White and Black patients prior to hormonal treatment, although all tumors were ER+ by immunohistochemistry."

"InnoSIGN presents the use of OncoSIGNal in triple breast cancer patients to identify new targeted treatment options."